ClinicalTrials.gg
RecruitingNCT07292038Updated Jan 14, 2026

Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors

A Phase 1 interventional study of NM6603 in Cancers, sponsored by NucMito Pharmaceuticals Co. Ltd.. Recruiting at 3 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by NucMito Pharmaceuticals Co. Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is to assess the MTD and PK of NM6603 in adult patients with advanced solid tumors.

Read the detailed description

This is a Phase 1, open label, 3+3 dose escalation study designed to evaluate the safety profile, the maximum tolerated dose (MTD), the pharmacokinetic and the preliminary antitumor activity of NM6603 in patients with advanced solid tumors.

02

Conditions studied

  • Cancers

Browse trials for

Keywords

  • advanced solid tumors
03

In context

Neoplasms

10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's planned enrollment of 30 is below the median of 60 across 7,712 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

NucMito Pharmaceuticals Co. Ltd. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced solid tumors (primarily advanced colorectal cancer or triple-negative breast cancer) confirmed by histology or cytology
  • Prior adequate standard therapy with documented progression or intolerance, or lack of available standard therapy options, or to standard therapy
  • At least one evaluable tumor lesion per version 1.1
  • Age 18 to 75 years at the time of
  • Body weight 45 kg or greater for men and 40 kg or greater for women
  • performance status 0 or 1
  • Expected survival time greater than 12 weeks
  • Adequate organ and bone marrow function as defined below:

    • 1500 per mm3 or greater
    • count 100000 per mm3 or greater with no transfusion or growth factor use within 14 days before first dose
    • 9.0 g/dL or greater with no transfusion or stimulating factors within 14 days before first dose
    • Total 1.5 times (ULN) or less (patients with Gilbert syndrome allowed)
    • and ALT 2.5 times ULN or less without liver , or 5 times ULN or less with liver metastasis
    • 60 mL/min or greater (Cockcroft-Gault formula)
    • 1.5 times ULN or less and APTT 1.5 times ULN or less
  • Male subjects and female subjects of agree to use effective from signing consent until 6 months after last dose; men must not donate sperm; women of childbearing potential require a negative pregnancy test within 7 days prior to first dose
  • Able and willing to comply with study visits, procedures, and provide written informed consent

Exclusion criteria

Exclusion Criteria:

  • Known to NM6603 or its components
  • Prior treatment with a drug targeting the same mechanism of action or molecular target
  • Participation in another drug or device clinical trial within 4 weeks before first dose
  • Major surgery within 4 weeks before first dose or planned surgery during the study
  • Chemotherapy, biologic therapy, macromolecular targeted therapy, or radiotherapy within 4 weeks before first dose
  • Oral fluoropyrimidines or other small molecule targeted agents received within 2 weeks or 5 half-lives before first dose (whichever is longer)
  • Use of traditional Chinese medicine or herbal products with antitumor activity within 2 weeks before first dose
  • Use of medications known to prolong or strong inhibitors or inducers of CYP1A2, CYP2A6, or within 7 days before first dose, or requirement for continued use
  • Systemic or drugs at doses greater than 10 mg/day prednisone or equivalent within 4 weeks before first dose (physiologic replacement and topical/inhaled forms allowed)
  • History of another within 5 years except for curatively treated carcinoma in situ of the cervix, non-melanoma skin cancer, localized prostate cancer, or ductal carcinoma in situ
  • Active central nervous system , including symptomatic , , spinal cord compression, or unstable brain metastasis
  • Treated brain metastases allowed if stable for 4 weeks or longer, no neurologic symptoms, and not receiving systemic corticosteroids above replacement dose for 4 weeks
  • Untreated asymptomatic brain metastases 1.5 cm or smaller allowed if not requiring corticosteroids
  • Uncontrolled disease including:

    • Active infection
    • Acute coronary syndrome, symptomatic heart failure ( class 2 or greater), cerebrovascular accident, , stroke, deep vein thrombosis, pulmonary embolism, aneurysm, arterial dissection, or other grade 3 or higher cardiovascular or cerebrovascular events within 6 months
    • less than 50 percent, uncontrolled hypertension (systolic over 160 mmHg or diastolic over 100 mmHg), uncontrolled hyperglycemia, ventricular arrhythmias requiring intervention, second or third degree AV block, congenital long QT syndrome, QTcF greater than 450 ms
    • Active peptic ulcer, gastritis, or bleeding disorder
    • Risk factors for pancreatitis including history of pancreatitis, uncontrolled hyperlipidemia, excessive alcohol use, uncontrolled diabetes, gallbladder disease, or medications associated with elevated triglycerides or pancreatic toxicity
    • Psychiatric or social conditions that may affect study compliance or ability to provide
  • Family history of long QT syndrome or unexplained sudden death before age 40 in a first-degree relative
  • Inability to swallow oral medication or gastrointestinal disease or major GI surgery likely to impair drug absorption, metabolism, or excretion
  • Known alcohol or substance dependence
  • Active syphilis; positive antibody; positive antibody with detectable HCV RNA; active infection (HBsAg positive with HBV DNA 1000 IU/mL or greater)
  • Not recovered to grade 1 or less from prior therapy toxicity ( v5.0), except for alopecia, irreversible grade 1 fatigue, or clinically insignificant lab abnormalities such as lymphocyte count decrease
  • Pregnant or breastfeeding women or women planning pregnancy during the study
  • Any condition that, in the investigator's judgment, makes the subject unsuitable or may affect compliance
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    NM6603, administered orally every day in 28-day cycles

    Drug: NM6603

Interventions

  • DrugNM6603

    NM6603 is an orally administered investigational small-molecule drug evaluated in this dose-escalation study in patients with advanced solid tumors.

06

What researchers measure

Primary outcomes

  1. maximum tolerated dose (MTD)

    MTD was defined as the highest dose at which dose-limiting toxicity (DLT) occurred in less than 33% of patients. DLT will be defined as toxicities that meet pre-defined severity criteria(according to the NCI CTCAE v5.0 toxicity assessment criteria), and assessed as having a suspected relationship to study drug that occurred within the first cycle(28 days) of treatment.

    Time frame: During the first cycle. Each cycle is 28 days

  2. Recommended Phase II Dose

    The recommended dosage for subsequent Phase II studies will be based on MTD (Maximum Tolerant Dose), pharmacokinetics, preliminary efficacy and safety data from the study

    Time frame: Up to 1 Year

Secondary outcomes

  1. Maximum observed concentration (Cmax) of NM6603

    To evaluate the maximum observed concentration (Cmax) of NM6603 in subjects with advanced solid tumors

    Time frame: Up to 31 days

  2. Time of maximum observed concentration (Tmax) of NM6603

    To evaluate the time of maximum observed concentration (Tmax) of NM6603 in subjects with advanced solid tumors

    Time frame: Up to 31 days

  3. Terminal elimination half-life (t1/2) of NM6603

    To evaluate the terminal elimination half-life (t1/2) of NM6603 in subjects with advanced solid tumors

    Time frame: Up to 31 days

  4. Area under the curve from the time of dosing to the time of the last measurable concentration (AUClast) of NM6603

    To evaluate the area under the curve from the time of dosing to the time of the last measurable concentration (AUClast) of NM6603 in subjects with advanced solid tumors

    Time frame: Up to 31 days

  5. Area under the curve from the time of dosing to infinity (AUCinf) of NM6603

    To evaluate the area under the curve from the time of dosing to infinity (AUCinf) of NM6603 in subjects with advanced solid tumors

    Time frame: Up to 31 days

  6. Efficacy of NM6603 by Overall response rates (ORR)

    Overall response rate (ORR) defined as the proportion of participants with complete response (CR) or partial response (PR) as determined by the investigator using RECIST V1.1.

    Time frame: Up to 1 year

  7. Efficacy of NM6603 by disease control rate (DCR)

    Disease control rate (DCR) is defined as the percentage of subjects who achieve complete response, partial response, or stable disease according to RECIST version 1.1.

    Time frame: Up to 1 year

  8. Efficacy of NM6603 by Overall Survival (OS)

    Overall survival is defined as the time from the first dose of study treatment until death from any cause.

    Time frame: Up to a year

  9. Safety of NM6603 by incidence and severity of treatment-emergent adverse events (TEAEs)

    The number of subjects experiencing treatment-emergent adverse events will be recorded, and the severity of each event will be graded according to NCI CTCAE version 5.0.

    Time frame: Up to 1 year

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Nov 2026, 11 months after the start.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's planned 11 months is below that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 18, 2025
StartActual
Dec 18, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07292038
Lead sponsor
NucMito Pharmaceuticals Co. Ltd.
Responsible party
Sponsor
First posted
Dec 18, 2025
Start date
Dec 18, 2025
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Jan 14, 2026

Study contacts

COO
Contact
ClinicalDevelopment@nucmito.com
86-592-7829029

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion